<?xml version="1.0" encoding="UTF-8"?>
<p>The study endpoints are: two consecutive negative 2019-nCoV RNA results after initiation of antiviral therapy at least 24 h apart; progression to severe COVID-19; completion of the entire therapeutic regimen and study patient visits; adjustment of medications due to poor prognosis or severe adverse events, or death.</p>
